6-[4-[2-fluoro-6-(pyrrolidin-1-ylmethyl)phenyl]phenyl]-2-methyl-1H-benzimidazole-4-carboxylic acid
C26H24FN3O2 — CID 146525361
Data last refreshed: (MolForge compound catalog, from PubChem)
About 6-[4-[2-fluoro-6-(pyrrolidin-1-ylmethyl)phenyl]phenyl]-2-methyl-1H-benzimidazole-4-carboxylic acid
6-[4-[2-fluoro-6-(pyrrolidin-1-ylmethyl)phenyl]phenyl]-2-methyl-1H-benzimidazole-4-carboxylic acid (PubChem CID 146525361) has the molecular formula C26H24FN3O2 and a molecular weight of 429.50 g/mol. Its IUPAC name is 6-[4-[2-fluoro-6-(pyrrolidin-1-ylmethyl)phenyl]phenyl]-2-methyl-1H-benzimidazole-4-carboxylic acid.
Molecular Properties
| Compound Name | 6-[4-[2-fluoro-6-(pyrrolidin-1-ylmethyl)phenyl]phenyl]-2-methyl-1H-benzimidazole-4-carboxylic acid |
|---|---|
| PubChem CID | 146525361 |
| Molecular Formula | C26H24FN3O2 |
| Molecular Weight | 429.50 g/mol |
| Exact Mass | 429.19 |
| IUPAC Name | 6-[4-[2-fluoro-6-(pyrrolidin-1-ylmethyl)phenyl]phenyl]-2-methyl-1H-benzimidazole-4-carboxylic acid |
| SMILES | Cc1nc2c(C(=O)O)cc(-c3ccc(-c4c(F)cccc4CN4CCCC4)cc3)cc2[nH]1 |
| InChI | InChI=1S/C26H24FN3O2/c1-16-28-23-14-20(13-21(26(31)32)25(23)29-16)17-7-9-18(10-8-17)24-19(5-4-6-22(24)27)15-30-11-2-3-12-30/h4-10,13-14H,2-3,11-12,15H2,1H3,(H,28,29)(H,31,32) |
| InChIKey | FKXWVWCHXFCKBG-UHFFFAOYSA-N |
| XLogP | 5.64 |
| TPSA | 69.22 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 429.50 |
| LogP ≤ 5 | 5.64 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 3 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 146525361 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.